These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 36462127)

  • 21. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
    Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
    BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Sarcopenia and Whole-Body Composition in Rheumatoid Arthritis.
    Brance ML; Di Gregorio S; Pons-Estel BA; Quagliato NJ; Jorfen M; Berbotto G; Cortese N; Raggio JC; Palatnik M; Chavero I; Soldano J; Wong R; Del Rio L; Sánchez A; Brun LR
    J Clin Rheumatol; 2021 Sep; 27(6S):S153-S160. PubMed ID: 32897991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
    Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
    Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Shao F; Li HC; Wang MJ; Cui CM
    Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3416-3424. PubMed ID: 34002814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to biologic disease-modifying antirheumatic drugs in adult patients with rheumatic diseases.
    Fazaa A; Makhlouf Y; Ben Ouhiba A; Miladi S; Sellami M; Ouenniche K; Souabni L; Kassab S; Chekili S; Zakraoui L; Ben Abdelghani K; Laatar A
    Therapie; 2021; 76(5):467-474. PubMed ID: 32948325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry.
    Prior-Español A; Sánchez-Piedra C; Campos J; Manero FJ; Pérez-García C; Bohórquez C; Busquets-Pérez N; Blanco-Madrigal JM; Díaz-Torne C; Sánchez-Alonso F; Mateo L; Holgado-Pérez S
    Sci Rep; 2021 May; 11(1):11091. PubMed ID: 34045525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis.
    Das P; Weisenfeld D; Dahal K; De D; Feathers V; Coblyn JS; Weinblatt ME; Shadick NA; Cai T; Liao KP
    Arthritis Res Ther; 2023 Jun; 25(1):93. PubMed ID: 37269020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
    Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
    J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis.
    Gossec L; Humphries B; Rutherford M; Taieb V; Willems D; Tillett W
    Arthritis Res Ther; 2024 Feb; 26(1):50. PubMed ID: 38360699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
    Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
    Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
    Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database.
    Tekgoz E; Colak S; Yardimci KG; Kucuksahin O; Cinar M; Yilmaz S; Kasifoglu T; Bes C; Yagiz B; Erden A; Kilic L; Kanitez NA; Ertenli AI; Coskun BN; Ediboglu ED; Mercan R; Kiraz S; Yazisiz V; Karadag O; Atagunduz P; Kalyoncu U
    J Clin Rheumatol; 2022 Mar; 28(2):e318-e323. PubMed ID: 34014053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis.
    Turkstra E; Ng SK; Scuffham PA
    Curr Med Res Opin; 2011 Oct; 27(10):1885-97. PubMed ID: 21848493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 38. The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis.
    Suto T; Okamura K; Sakane H; Okura C; Kaneko T; Chikuda H
    Medicine (Baltimore); 2023 Nov; 102(47):e36132. PubMed ID: 38013343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.